A reassuring collection of quotes. The key one being the contrast between revenue and ebitda growth showing the operating leverage that should still drive profit growth in excess of revenue growth.
The signs are that this is a tax related sell-down, though I have no idea why.
It is a little concerning given that Editure have expertise in the industry, but it could also have to do with the fact that Editure sees its interest in KME as limiting its own business opportunities in some way.
- Forums
- ASX - By Stock
- KME
- Ann: Change in substantial holding
Ann: Change in substantial holding, page-11
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KME (ASX) to my watchlist
(20min delay)
|
|||||
Last
48.0¢ |
Change
0.025(5.49%) |
Mkt cap ! $27.00M |
Open | High | Low | Value | Volume |
46.0¢ | 48.5¢ | 46.0¢ | $24.25K | 51.57K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5000 | 46.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
48.0¢ | 1739 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 439 | 0.915 |
1 | 7582 | 0.910 |
1 | 5524 | 0.905 |
2 | 20484 | 0.900 |
1 | 1149 | 0.870 |
Price($) | Vol. | No. |
---|---|---|
0.945 | 557 | 1 |
0.950 | 12474 | 2 |
0.960 | 53883 | 2 |
0.970 | 20668 | 1 |
0.980 | 27357 | 2 |
Last trade - 14.10pm 25/11/2024 (20 minute delay) ? |
Featured News
KME (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online